Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05631444

Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia

Comparison of the Therapeutic Potential of Autologous Bone Marrow Mononuclear Cells Versus Allogenic Wharton Jelly-derived Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb-threatening Ischemia

Sponsor: Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

Conditions Chronic Limb-threatening Ischemia Diabetes Mellitus

Interventions Cell-based therapy

Updated 3 times since 2022 Last updated: Nov 20, 2022 Started: Jan 1, 2019 Primary completion: Sep 30, 2020 Completion: Oct 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Chronic Limb-threatening Ischemia and Diabetes Mellitus and is currently completed. Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle leads this study, which shows 3 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

Data source: Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bucaramanga, Colombia